As demonstrated in Figure 7, this biomimetic platform achieved superior anti-glioma efficacy in C6 tumor-bearing mice, evidenced by significantly enhanced tumor apoptosis (TUNEL), reduced angiogenesis (CD31), diminished tumor volume (H&E), and minimal residual tumor mass (MRI) compared to unmodified nanosuspensions and free paclitaxel controls. Here, PECAM1 is linked to neoplasm.